The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Clinical Study of 125 Ⅰ Radioactive Particles Implanted to Treat Hilar Cholangiocarcinoma
Author(s): 
Pages: 289-292
Year: Issue:  4
Journal: ACTA ACADEMIAE MEDICINAE WEIFANG

Keyword:  125Ⅰ放射性粒子PTCD肝门部胆管癌;
Abstract: 目的 观察125 Ⅰ放射性粒子对肝门部胆管癌的临床治疗效果.方法 78例肝门部胆管癌患者随机分成3组,A组经皮经肝胆管引流术(PTCD)27例、B组(125 Ⅰ粒子)39例及C组(PTCD+125 Ⅰ粒子)12例,通过观察术前术后总胆红素的改变、肿瘤大小的变化及患者的生存率,分析125 Ⅰ放射性粒子永久性植入治疗胆管癌的疗效.结果 术后半个月,A,B,C 3组总胆红素下降率分别为81.5%(22/27),66.7%(26/39),83.3%(10/12),A,B两组及B,C两组差异均有显著性(P<0.05);术后1年3组(CR+PR)分别为29.6%(8/27),74.4%(29/39),75.0%(9/12),A,B两组及A,C两组差异均有显著性(P<0.05);术后6个月和12个月生存率,B组为89.7%,82.1%,C组为91.7%,83.3%,明显高于A组的59.3%,33.3%(P<0.05).结论 对肝门部胆管癌,125 Ⅰ放射性粒子有治疗作用,PTCD术为姑息性治疗,125 Ⅰ放射性粒子联合PTCD术可取得更佳效果.
Related Articles
loading...